Investor Presentaiton
Strong Q2 in Wound & Skin Care with 13% growth driven by solid
momentum in Wound Care Europe, including benefit from a low baseline
9
6
2
Wound & Skin Care performance
I
10
14
5
5
12
1
4
-5
-4
-6
747
695
688
678
658
13
•
Q2 2022/23 highlights
Wound Care in isolation grew 12% despite continued negative impact from
backorders, as expected
The backorder situation has been resolved and production will
gradually ramp up to full capacity in H2 2022/23
Solid growth momentum in Europe driven by the Biatain Silicone
portfolio in Germany, France, and the UK. The region also benefited
from a low baseline last year
China returned to growth in Q2 driven by significantly improved
hospital access, resulting in an increase in procedural volumes and
demand for wound care products
The Compeed contract manufacturing business continued to perform well
and contributed significantly to growth, reflecting a healthy consumer
demand
Skin Care returned to growth in Q2, coming from a lower baseline last year
9
Q2 21/22
Q3 21/22 Q4 21/22
Q1 22/23 Q2 22/23
Revenues (DKKm)
Organic growth (%)
WC Organic growth (%)
Reported growth (%)
ColoplastView entire presentation